Phase I/II trials on selumetinib have demonstrated its stability or reduction of tumor size in pediatric patients with NF1-associated and sporadic form of pLGGs, with similar results observed in a study of children with progressive/recurrent PA (Table 2) (164, 165). This evidence concerns the gene NF1 and neoplasm.